RGX-202

Drug identity has not yet been verified against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)NCT05693142RGNXPhase 2, Phase 3Active not recruiting2026-09Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.